<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BORTEZOMIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BORTEZOMIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzymatic inhibitor. </COMMENT>
</INTERACTION>
</INTERACTIONS>
